Janux Therapeutics (JANX) Change in Acquisitions & Divestments (2021 - 2025)
Janux Therapeutics (JANX) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $152.9 million as the latest value for Q4 2025.
- Quarterly Change in Acquisitions & Divestments rose 163.67% to $152.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $405.3 million through Dec 2025, up 90.35% year-over-year, with the annual reading at $405.3 million for FY2025, 90.35% up from the prior year.
- Change in Acquisitions & Divestments for Q4 2025 was $152.9 million at Janux Therapeutics, up from $126.4 million in the prior quarter.
- The five-year high for Change in Acquisitions & Divestments was $152.9 million in Q4 2025, with the low at $22.1 million in Q3 2021.
- Average Change in Acquisitions & Divestments over 5 years is $77.2 million, with a median of $76.0 million recorded in 2022.
- The sharpest move saw Change in Acquisitions & Divestments skyrocketed 427.21% in 2022, then tumbled 52.89% in 2024.
- Over 5 years, Change in Acquisitions & Divestments stood at $112.0 million in 2021, then decreased by 22.77% to $86.5 million in 2022, then plummeted by 48.27% to $44.8 million in 2023, then increased by 29.61% to $58.0 million in 2024, then surged by 163.67% to $152.9 million in 2025.
- According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $152.9 million, $126.4 million, and $94.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.